259 related articles for article (PubMed ID: 29174802)
1. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments.
Hu J; Hu WX
Cancer Lett; 2018 Feb; 414():214-221. PubMed ID: 29174802
[TBL] [Abstract][Full Text] [Related]
2. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.
Ramakrishnan V; Kumar S
Leuk Lymphoma; 2018 Nov; 59(11):2524-2534. PubMed ID: 29322846
[TBL] [Abstract][Full Text] [Related]
3. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
4. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
5. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
7. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.
Harvey RD; Lonial S
Future Oncol; 2007 Dec; 3(6):639-47. PubMed ID: 18041916
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
[TBL] [Abstract][Full Text] [Related]
9. Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma.
Zhu J; Wang M; Cao B; Hou T; Mao X
Curr Med Chem; 2014; 21(27):3173-87. PubMed ID: 24934342
[TBL] [Abstract][Full Text] [Related]
10. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
13. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.
Pandurangan AK
Asian Pac J Cancer Prev; 2013; 14(4):2201-5. PubMed ID: 23725112
[TBL] [Abstract][Full Text] [Related]
14. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
15. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
16. Endometrial Carcinoma: Specific Targeted Pathways.
Eritja N; Yeramian A; Chen BJ; Llobet-Navas D; Ortega E; Colas E; Abal M; Dolcet X; Reventos J; Matias-Guiu X
Adv Exp Med Biol; 2017; 943():149-207. PubMed ID: 27910068
[TBL] [Abstract][Full Text] [Related]
17. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
18. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
19. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway.
Feng N; Luo J; Guo X
Mol Med Rep; 2016 Apr; 13(4):3243-8. PubMed ID: 26936429
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]